Ip Share Discussion Threads

[bamboo2] 18/11/2024 07:27

IP Group plc - Australian portfolio company AMSL Aero completes first free flight of its 'Vertiia' aircraft



IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that Australian portfolio company AMSL Aero has announced that it has completed the first free flight of Vertiia, Australia's first passenger-capable, emission-free, long range electric vertical take-off and landing aircraft (eVTOL) aircraft.

The landmark flight is the first by an Australian-designed and built eVTOL, the new generation of aircraft that take off and land like a helicopter but fly fast and smoothly like a fixed-wing aeroplane. Since the first untethered flight, which took place earlier this month, the aircraft has since taken off, flown and landed successfully more than 50 times.



Vertiia is the most complex civil aircraft ever developed in Australia. It has been designed to fly up to 1,000km on hydrogen at a cruising speed of 300km/hour with zero carbon emissions, carrying up to four passengers and a pilot.



The historic test flight was performed on battery power by remote control in the Central West region of New South Wales in accordance with Civil Aviation Safety Authority (CASA) regulations. AMSL Aero will begin hydrogen-fuelled flight testing of Vertiia in 2025 having already broken records in 2023 by completing the first tethered battery-powered hover.



This year, AMSL Aero received deposits for 26 Vertiia aircraft orders from civil customers including 20 from Aviation Logistics, which operates the Air Link, AirMed and Chartair brands covering passenger services, aircraft charter, air freight and aeromedical flights across Australia.



IP Group Australia has an undiluted holding of 34.0% in AMSL Aero while IP Group's managed private funds* hold an additional 14.7%.



*Includes funds managed/advised on behalf of Hostplus & TelstraSuper

[peterrr3] 13/11/2024 18:44

Always thought this was a very long shot in the portfolio but good luck to them.

[bamboo2] 13/11/2024 12:11

Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
13 Nov 2024

Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.

Ulcerative colitis, an inflammatory bowel disease, is a debilitating disease that affects over 1.4 million people globally. MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC patients, without immunosuppression or unwanted side effects.

The COMPOSER-1 study will investigate the safety, tolerability, and initial signals of efficacy of MB310 in a randomised, placebo-controlled, double-blind, clinical trial. The degree to which the bacteria within MB310 successfully engraft into patients’ intestinal microbial community will be measured. The study will recruit patients with active, mild-to-moderate UC, who will take two capsules of study medication (active or matched placebo) once a day for 12 weeks in addition to their standard of care medication, with a 12-week follow-up period. (Study identifiers: NCT06582264; 2023-507376-50) .

The bacterial strains in MB310 were identified by analysing clinical and microbiome data from a faecal microbiota transplant (FMT) study in UC patients carried out with collaborators at the University of Adelaide. The results demonstrated the ability of a microbiome therapy to induce remission in UC without significant side-effects. Microbiotica‘s analysis identified the engrafting bacteria associated with clinical response, leading to the development of MB310 as an LBP. Preclinical studies have demonstrated that MB310 acts via at least three independent mechanisms that are central to the pathology of UC: promoting the healing of the damaged gut epithelial barrier, regulating the balance of cytokines that are inflammatory (TNF) and immune-modulatory (IL-10); and inducing a regulatory T-cell response.

Professor Walter Reinisch, Professor for Gastroenterology and Hepatology at the Vienna Medical University, Austria, an advisor to Microbiotica and a principal investigator in the study, said, “Microbiota dysregulation is known to be a key driver to the pathogenesis in ulcerative colitis. The COMPOSER-1 study offers us a unique opportunity to treat UC by rebalancing the microbiota with this new treatment modality and potentially inducing long-term disease remission in our patients.”

Ron Carter, Microbiotica’s Chief Medical Officer, said, “there is a considerable body of evidence to support that FMT is beneficial for mild-to-moderate UC patients. This provides the underpinning of a microbiome-based treatment for this debilitating disease. Microbiotica’s precision microbiome platform has enabled us to identify the specific bacteria that could make a difference for patients and deliver them as a pharmaceutical in the form of MB310.”

– ENDS –

About Microbiotica

Microbiotica is a private, clinical-stage, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. The company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.

The Company is creating a novel pipeline of programmes in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis). It has a major partnership with Cancer Research UK and Cambridge University Hospitals in immuno-oncology. The company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-PD-1 immunotherapy. MB310 was developed in collaboration with the University of Adelaide. Both programmes have data read-outs in 2025.

Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK. Microbiotica has raised more than £62 million equity investment, including a £50 million Series B in 2022, with venture investors including British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The company has also received financial support from the US-based Crohn’s and Colitis Foundation.

[bamboo2] 11/11/2024 17:56

Having found a base, chart finally starting to look more positive.

[peterrr3] 08/11/2024 17:55

Thanks, This looks like a new trial. They haven't reported the results of the other 3 yet. IP Group could easily provide an update, rather than choosing to keep the Shareholders in the dark.

[bamboo2] 08/11/2024 14:32

Checking up on Istesso trial, found this that seems to suggest still recruiting and a 31 December 2024 end date.

[bamboo2] 05/11/2024 16:29

New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore
05 Nov 2024

New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore designed to:
Advance biomedical research and translate discoveries for improved patient care

Improve health outcomes by targeting novel genomic and epigenomic discoveries in cancer, human genetic disease and infectious disease

Initial programme: to create an ‘early warning system’ for future pandemics across as many as 30 NHS sites, to support improved biosecurity nationwide

Oxford Nanopore’s high-performance genomics technology to provide richer genomic data, faster, more accessibly and more affordably.

Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore, to support the government’s vision to build an NHS “fit for the future" by enabling genomics-based translational research and accelerating the development and adoption of Oxford Nanopore’s ground-breaking genomics technology in the NHS.

By utilising Oxford Nanopore’s richer genomic insights, rapid, scalable and affordable sequencing technology, the initiative aims to deliver transformative improvements in patient care and foster economic growth in the UK’s thriving life sciences sector.

Oxford Nanopore CEO Gordon Sanghera, commented:

“The UK has a remarkable genomics ecosystem, and we are delighted to be innovating more collaboratively through this partnership. Genomics England and UK Biobank have led the way in scaling genomics discovery and translating these advances into patient impact. NHS England, through its Networks of Excellence and advancements developed by the Genomic Laboratory Hubs (GLHs), has been instrumental in adopting these innovations into national healthcare strategies. By working alongside our partners on shared goals of improved patient outcomes - whether in cancer, human genetic disease or infectious disease - we believe we can deploy our unique DNA/RNA sequencing technology in ways that are most impactful for the people of the UK.”

Health and Social Care Secretary Wes Streeting, commented:

“If we fail to prepare, we should prepare to fail. Our NHS was already on its knees when the pandemic struck, and it was hit harder than any other comparable healthcare system.

“We cannot let history repeat itself. That’s why this historic partnership with Oxford Nanopore will ensure our world-leading scientists have the latest information on emerging threats at their fingertips.

“As we embrace the technological revolution, our 10 Year Health Plan will shift the NHS away from analogue to digital, saving countless more lives.”

Science and Technology Secretary Peter Kyle, commented:

“During the Covid pandemic we saw the power of the UK life sciences sector very clearly – from the Oxford-Astra Zeneca vaccine that saved so many lives, through to operating one of the world’s most effective Covid surveillance systems, which spotted several emerging variants of the disease.

“This partnership will build on that expertise to monitor emerging diseases as they arise, putting our scientists and decision-makers one-step ahead and providing the information they need to make informed decisions.

“Together with the ability to better diagnose cancers and rare diseases, we are leveraging UK life sciences to protect the public and ultimately save lives.”

Professor Susan Hopkins, Chief Medical Advisor at UK Health Security Agency, commented:

“Early detection is absolutely crucial in enabling us to respond effectively to any emerging pathogen. The UK already has a wealth of expertise in genomic surveillance, and this programme will build on that expertise and enable us to bring our resources and capability to tackle developing threats at greater speed. Enhancing the capacity for the NHS to determine new and emerging pathogens causing severe acute respiratory infections will improve the detection and emergence of infections.

“As part of the 100 days mission, this will enable the development of effective diagnostics for novel pathogens and enhance our pandemic preparedness.”

Professor Ian Abbs, Chief Executive of Guy’s and St Thomas’ NHS Foundation Trust, commented:

“We’ve been working on the respiratory metagenomics programme for over four years and have clearly seen the benefit to our patients. It’s a momentous day now that we can ensure other hospitals, and more patients, can also benefit from faster and more accurate treatment for severe respiratory conditions thanks to new genomic technology.”

Advancing the understanding of genomics, for future disease prevention and personalised medicine
Oxford Nanopore’s partnership with Genomics England and UK Biobank is aimed at translating research-based discoveries from the lab into clinical settings, benefiting UK healthcare. Priority areas include cancer, where genomic insights (the analysis of DNA) can help identify personalised treatment options and enhance early detection, and rare disease characterisation, where information-rich genomic and epigenetic analysis – changes to DNA that contribute to disease – can improve diagnosis and inform targeted therapies. This partnership presents a further opportunity to collaborate on broader emerging applications, which in the future could include newborn screening, where genomics can enable early identification of genetic disorders for prompt intervention, and pharmacogenomics, where genetic insights guide safer and more effective medication choices tailored to an individual's genetic profile.

Creating a world-first pathogen surveillance system in the NHS
As a key part of the partnership, the UK will establish the first real-time, pathogen-agnostic biosurveillance system across as many as 30 hospitals in NHS England—a crucial early warning framework to detect and respond to emerging pandemics and biological threats. Building on successful NHS England Network of Excellence pilots led by Guy’s and St Thomas’ NHS Foundation Trust (GSTT), this system will expand the NHS Respiratory Metagenomics programme to enable rapid pathogen identification across the UK. This data will be provided by the NHS to the UK Health and Security Agency, allowing potentially quicker decisions on emerging diseases to be taken and bolstering national biosecurity as set forth in the UK Biological Security Strategy. This project is expected to start in 2025 and will continue over multiple years.

In addition to providing biosecurity capabilities, the expanded respiratory metagenomics programme will deploy Oxford Nanopore’s sequencing technology to support infectious disease management in the critical care setting. This rollout is designed to provide a groundbreaking, six-hour timeline for fully characterising respiratory diseases including drug (antimicrobial) resistance, an essential leap forward in patient care. By rapidly transitioning NHS diagnostics from analogue to digital, the programme’s goal is to enable quicker, targeted care for patients and reduce hospital strain, advancing the ambitions set out in the Government’s 10-Year Health Plan.

Translating genomics into enhanced NHS patient care
The integration of Oxford Nanopore’s innovative sequencing technology will enable the NHS to explore further this technology to characterise diseases including cancer and rare genetic conditions with greater speed and precision. With potential for collaborative development of rapid and improved diagnostic tools, Oxford Nanopore’s technology has the potential to enable patients across the NHS to benefit from earlier, more accurate disease detection and treatment pathways.

Driving economic growth and workforce development in life sciences
This work will not only enhance patient outcomes but also position the UK as a global leader in genomic research and innovation, further strengthening the nation’s biosecurity and healthcare resilience. By accelerating pathways for life sciences innovation into the NHS through globally recognised research programmes, this collaboration enhances the UK’s position as a global biotechnology hub, supporting economic growth and creating high-value jobs in the life sciences ecosystem. As part of this initiative, NHS staff and researchers will gain access to relevant training and support to advance a skilled workforce ready to harness the potential of genomics and personalised medicine.

[bamboo2] 05/11/2024 08:24

TRX up for sale.

[p1nkfish] 03/11/2024 08:29

Probably not much money invested to support the collaboration but Reaction Engines in administration around Budget day.

[bagpuss67] 01/11/2024 20:26

Yes. Agreed.

[peterrr3] 01/11/2024 20:09

The cynic in me sees the long overdue Istesso results and write-off miraculously timed to coincide with the RNS on the Featurespace cash receipt. Let's hope the glass half full me prevails on long odds.

[bamboo2] 01/11/2024 11:04

Despite good news flow and management intentions, the buyback volume seemingly overwhelmed by sellers at present.

Are these forced sellers, unable to bide their time, needing to get out at any price?

[nigelpm] 30/10/2024 21:49

No. There's 120m odd of debt also

[palisz] 30/10/2024 21:17

So the remaining portfolio of 80+ company stakes are valued at less than zero.
Including some fairly serious outfits. ( Worth revisiting the IPO web site and looking at just the top 20 for anybody needing reminding!)

[rambutan2] 30/10/2024 20:43

Toffer says...

[bamboo2] 30/10/2024 19:13

Cash £183.7m [end August 2024]
Featurespace £134m
Kynos £7m
Other stakes £10m
IUG up to £10m?
ONT £150m

£494.7m

total shares 993.80m

£494.7m/993,000,000 = 49.77p

[palisz] 30/10/2024 18:49

Once the disposals have completed anyone have a new cash figure...
Cash plus ONT must be over 40p..thinking aloud could be v wrong!
But this 'thing' looks crazy cheap!

[bamboo2] 30/10/2024 17:12

Thanks palisz, I think we should have the complete post!

Diffblue Ltd

Diffblue Secures $6.3 Million in New Funding Amidst 3x Growth Period
30 Oct 2024

OXFORD, England - Diffblue, creators of the world’s first fully autonomous generative AI-for-code software, today announced it has secured $6.3 million in new capital as it reaches a record six-month period with 326% net new ARR growth from the prior six months. Toffer Winslow (formerly StackState, Dynatrace, RSA Security) has also been appointed as Diffblue’s new CEO to drive the firm’s next stage of growth.

Diffblue's new and oversubscribed round of funding was anchored by existing investors IP Group, Parkwalk Advisors, and AlbionVC, with additional participation from Oxford University, and private investors via the Oxford Technology and Innovations EIS Fund (OTIF). Additionally, Citi Institutional Strategic Investments joined as a new equity investor. The company is now well-positioned to continue to fuel its triple-digit growth rate well into 2026 while still maintaining a capital efficient approach that is uncommon among generative AI companies.

The company’s rapid top-line growth is driven by swift and steady customer adoption of Diffblue’s AI-powered autonomous test generation platform that catches bugs early in the development cycle when they are easy and inexpensive to fix. Diffblue’s novel approach is different from LLMs and supports the mission of developers and IT leaders who are committed to automating intelligently, shortening release cycles, and delivering better quality software for the benefit of users. Today, Diffblue serves four of the 10 largest U.S. banks and several other members of Forbes’ Global 2000. Key customers include: Citi, ING, Cisco, AstraZeneca, and The Bank of New York Mellon Corporation (BNY).

“There is a massive market opportunity for start-ups that figure out how to harness the potential of AI to transform how software gets built, tested, and deployed,” said Iain Maclean, Global Head of Rates Technology at Citi. “Our investment in the company reflects our belief in its potential to be an important player in the next generation of AI-powered software development tools.”

Founded by researchers from the University of Oxford, Diffblue drives velocity, quality, and productivity for Java development teams working on mission-critical applications. Its flagship product, Diffblue Cover, leverages generative AI to automate unit test generation 250x faster than a human developer. As a result, software teams can improve code quality, expand test coverage, and increase efficiency so they can ship software faster, more frequently, and with fewer defects. Diffblue’s differentiated approach to generative AI leverages reinforcement learning techniques to avoid the accuracy, security, privacy, and liability concerns associated with LLM-based coding assistants.

“Diffblue is leading the charge in one of the hottest, fastest-moving markets in the history of the software industry,” said Mark Reilly, Managing Partner at IP Group. “The company’s traction with large, sophisticated customers deploying best-in-class AI technologies across their software development processes is strong evidence of its differentiated, valuable solution.”

“Diffblue is at a hugely exciting juncture owing to its team's ability to provide a valuable solution within a rapidly evolving market,” said Neil Cameron, Investment Director at Parkwalk. “At Parkwalk, we invest in companies with the potential to lead transformative industries. Diffblue’s growth, coupled with its increasing traction amongst global customers, only strengthens our confidence in their long-term impact on the future of software development.”

Toffer Winslow, CEO at Diffblue, added, “Diffblue̵7;s deterministic AI technology, committed employees, blue chip customers, and visionary investors are a rare and enviable foundation on which a great company can be built. I’m grateful for all the good work that has been done to build the company to-date and excited for the opportunity ahead as we build a market leader in our space.” More about Winslow’s thoughts on the opportunity in front of Diffblue can be found in this blog post.

Next month, Diffblue will be making its flagship solution more accessible to developers at companies of all sizes with a new product release. Stay tuned for updates.

To learn more about Diffblue, visit diffblue.com.

About Diffblue

Founded by researchers from the University of Oxford, Diffblue uses game-changing AI technology to fundamentally transform the way developers write code. An early pioneer of generative AI, Diffblue leverages reinforcement learning to automate tedious and error-prone parts of the SLDC (software development lifecycle) with trusted results. Capable of writing unit tests 250x faster than a human developer, Diffblue Cover autonomously helps software teams improve code quality, expand test coverage and increase productivity so they can ship software faster, more frequently, with fewer defects. Diffblue’s customers include Citi, Cisco, AstraZeneca, ING, and The Bank of New York Mellon Corporation (BNY).

Press Contact
Kira Wolfe
[e-mail]

[palisz] 30/10/2024 15:21

30 Oct 2024

OXFORD, England - Diffblue, creators of the world’s first fully autonomous generative AI-for-code software, today announced it has secured $6.3 million in new capital as it reaches a record six-month period with 326% net new ARR growth from the prior six months. Toffer Winslow (formerly StackState, Dynatrace, RSA Security) has also been appointed as Diffblue’s new CEO to drive the firm’s next stage of growth.

IPO has 29.5%

hxxps://www.ipgroupplc.com/news-and-events/portfolio-news/2024/2024-10-30

[palisz] 29/10/2024 19:21

tks,
Decent volume today, someone unloading at 47 a couple of million. and the stock barely moved. Be interesting to see how many IPO bought.
Another disposal adds to the buy back pot.
Once the 10m is completed expect another bigger tranche.

[bamboo2] 29/10/2024 09:59

palisz

2023 accounts suggest £4m
2024 half year gained £2.6m

So approx £6.6m plus

[bamboo2] 29/10/2024 09:48

Info from IPGroup


Dr. Falk Pharma acquires Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
29 Oct 2024

Freiburg, Germany, 29. October 2024

Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. The company was founded as a spin-out of the University of Edinburgh, Scotland, together with lead investor Epidarex Capital, a leading early-stage transatlantic venture fund, along with IP Group, and Scottish Enterprise. Effective immediately, Kynos Therapeutics will be integrated into the Falk Group.

Kynos Therapeutics’ lead investigational asset is KNS366, a highly potent and selective first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase (KMO). In a Phase I clinical trial, KNS366 was shown to be safe and well-tolerated at multiple doses. The compound also led to a dose-dependent inhibition of the enzyme KMO and modulation of its downstream metabolites.

Dr. Falk Pharma is excited about the addition of KNS366 to its R&D pipeline and will further explore the potential of KNS366 in future clinical trials, initially focusing on acute pancreatitis. This new asset will enhance Dr. Falk Pharma´s expansion into rare digestive and metabolic diseases and conditions.

About KNS366

Kynos Therapeutics’ lead investigational asset KNS366 selectively inhibits the enzyme kynurenine 3-monooxygenase (KMO). KMO is a key enzyme in the tryptophan metabolic pathway and has also been shown to play an important role in modulating immune processes. By inhibiting KMO activity, KNS366 interferes with inflammation and other immune system pathologies by lowering levels of its downstream metabolite – 3- hydroxykynurenine (3HK) – high levels of which have been linked to tissue damage and dysregulation of the immune system during inflammation. Inflammatory diseases including acute pancreatitis trigger an exacerbated, systemic pro-inflammatory response, making KMO inhibitors a promising next-generation treatment option for disorders characterized by severe inflammation.

About acute pancreatitis

Acute pancreatitis is a sudden inflammation of the pancreas that can be triggered by a number of factors. In its severe form, this acute inflammation can cascade to a reaction in the entire body over several days to weeks that can result in systemic inflammation, organ failure, and death. Accordingly, acute pancreatitis requires immediate medical intervention to manage patients’ symptoms and prevent worsening of their condition, often necessitating prolonged hospitalization. Currently, acute pancreatitis occurs in about 240,000 people in Europe and 300,000 people in the United States each year, with 1 in 5 acute pancreatitis patients requiring intensive care. To date, there are no proven or approved treatment options to prevent organ failure and death resulting from severe acute pancreatitis, meaning there is an urgent need for effective treatments.

About partnering with Dr. Falk Pharma

Dr. Falk Pharma engages in a variety of collaboration and partnership models to develop and deliver innovative treatment concepts with great potential. These treatments can be based on any type of pharmacological approach, from small molecules to biologics to novel drug delivery technologies. The company is involved in partnership projects across the range of phases and partners, from all stages of pre-clinical/clinical development and marketing as well as with academic researchers, start-ups, and established companies.

Dr. Falk Pharma is an industry leader in innovative pharmaceutical formulations that deliver active substances to specific functional segments of the gastrointestinal tract. Many of their products have attained standard-of-care status. The company enjoys strong, long-standing collaborations with renowned clinical centres and with academic and clinical key opinion leaders in the fields of gastroenterology, hepatology and metabolic diseases.

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1250 individuals globally and 323 in Freiburg.

Further information on Dr. Falk Pharma can be found online:

[palisz] 29/10/2024 09:20

I don't get a response from the company, so if someone could drop IR an email and ask the sale price would be good to know. As a public company they can't hide the number!

[palisz] 29/10/2024 09:16

In March 2022 it was valued at $17.80m so not massive, But IPO has not mentioned any change, despite progress, in the valuation. So must be a premium to this NAV number
Continues to show that NAV is conservative. A definite plus.